Loading…
Loading…
ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new biomarker data from its Phase 1b/2 trial to support plans for an enlarged randomized phase 2B SIGNAL-AD study of pepinemab for treatment for early Alzheimer's disease at the Alzheimer's Association International Conference in London, United Kingdom, on July 13, 2026.
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
Valuation and Earnings This table compares Evofem Biosciences and Vaccinex"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evofem Biosciences $11.39 million 0.11 $52.98 million ($0.06) -0.17 Vaccinex $388,000.00 7.33 -$20.25 million ($48.27) -0.02 Evofem Biosciences has higher revenue and earnings than Vaccinex. Evofem Biosciences
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer.
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease.
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
No recent filings indexed.